Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 8/20 | 0.42 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460236 | 1.00 | BCHE (0.42) | BCHEACHEMEP1BLTA4HMEN1 | |
| SCHEMBL3458699 | 0.99 | BCHE (0.40) | BCHEACHEMEP1BLTA4HMEN1 | |
| SCHEMBL3458832 | 0.91 | BCHE (0.43) | BCHEACHEMEP1B | |
| SCHEMBL3459756 | 0.91 | BCHE (0.43) | BCHEACHEMEP1B | |
| SCHEMBL3458892 | 0.90 | BCHE (0.41) | BCHEACHEMEP1BAPLNR | |
| SCHEMBL3459748 | 0.85 | BCHE (0.41) | BCHEACHEMEP1BLTA4HMEN1 | |
| SCHEMBL3458964 | 0.82 | ALDH3A1 (0.42) | MEN1MAPTKMT2APDE3BPDE3A | |
| SCHEMBL3172718 | 0.81 | PTGDR2 (0.35) | LTA4HMEN1MAPTKMT2APDE3B | |
| SCHEMBL7543969 | 0.77 | EGFR (0.41) | LTA4HMEN1MAPTKMT2APDE3B | |
| SCHEMBL5549430 | 0.77 | KMT2A (0.42) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988098-A1 | HETEROCYCLO ALKYL COMPOUNDS USED AS CCR2/CCR5 ANTAGONIST | Shenzhen Lingfang Biotech Co., Ltd (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-14 | — | — | US | disclosed |
| US-8741943-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1889839-B1 | Bicyclic compound, production and use as HIV inhibitors | TOBIRA THERAPEUTICS INC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8362058-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120232028-A1 | Bicyclic Compound, Production and Use Thereof | TOBIRA THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8183273-B2 | 8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide; HIV infectious diseases, chronic rheumatoid arthritis, autoimmune disease, allergic diseases, ischemic brain cell disease | TOBIRA THERAPEUTICS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2206702-A1 | Bicyclic compound, production and use thereof | Tobira Therapeutics, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090030032-A1 | Bicyclic Compound, Production and Use Thereof | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7371772-B2 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| EP-1889839-A1 | Bicyclic compound, production and use as HIV inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20040259876-A1 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259876-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | BCHE 1675/4885ACHE 2855/4885MEP1B 767/4885 |
| US-20090030032-A1 | Bicyclic Compound, Production and Use Thereof | CCR5, CCR1, CCR2 | BCHE 1435/4885ACHE 2248/4885MEP1B 631/4885 |
| US-20120232028-A1 | Bicyclic Compound, Production and Use Thereof | CCR5, CCR1, CCR2 | BCHE 1435/4885ACHE 2248/4885MEP1B 631/4885 |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | BCHE 1431/4885ACHE 2223/4885MEP1B 641/4885 |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | BCHE 1435/4885ACHE 2248/4885MEP1B 631/4885 |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | BCHE 1435/4885ACHE 2248/4885MEP1B 631/4885 |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | BCHE 1435/4885ACHE 2248/4885MEP1B 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.